ARTICLE | Company News
Isis Pharmaceuticals, Pfizer deal
November 12, 2012 8:00 AM UTC
Isis will receive a $1.3 million milestone payment from Pfizer triggered by the pharma's decision to advance EXC 001 ( PF-06473871) into Phase II testing. Pfizer gained rights to EXC 001 through its ...